Matching articles for "Prevnar 13"
Issue 1734 · August 4, 2025 Free
Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old (online only)

View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old

Med Lett Drugs Ther. 2025 Aug 4; 67(1734):e1 doi:10.58347/tml.2025.1734f
View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old
Issue 1734 · August 4, 2025 Free
Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old (online only)

View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old

Med Lett Drugs Ther. 2025 Aug 4; 67(1734):e1 doi:10.58347/tml.2025.1734g
View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old
Issue 1402 · October 29, 2012
Pneumococcal Vaccine for Adults

The US Advisory Committee on Immunization Practices (ACIP) has recommended that adults with immunocompromising conditions receive the 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13 ), even if they…

Med Lett Drugs Ther. 2012 Oct 29; 54(1402):87-8
The US Advisory Committee on Immunization Practices (ACIP) has recommended that adults with immunocompromising conditions receive the 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13 ), even if they have already received the older 23-valent unconjugated vaccine (PPSV23; Pneumovax 23 ). Prevnar 13 , initially approved by the FDA for use in infants and young children, has been licensed since December 2011 for adults ≥50 years old.
Issue 1345 · August 23, 2010
An Expanded Pneumococcal Vaccine (Prevnar 13) for Infants and Children

The FDA has licensed a 13-valent conjugate pneumococcal vaccine (PCV13; Prevnar 13 – Pfizer) for the prevention of invasive pneumococcal disease (IPD) in infants and children <6 years old. It replaces…

Med Lett Drugs Ther. 2010 Aug 23; 52(1345):67-8
The FDA has licensed a 13-valent conjugate pneumococcal vaccine (PCV13; Prevnar 13 – Pfizer) for the prevention of invasive pneumococcal disease (IPD) in infants and children <6 years old. It replaces Prevnar (PCV7). An unconjugated 23-valent polysaccharide vaccine (PPSV23; Pneumovax 23 – Merck) is FDA-approved for use in adults.